(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
2 March 2006 (02.03.2006)

PCT

(10) International Publication Number
WO 2006/022755 A1

(51) International Patent Classification[7]: A61K 31/675, A61P 19/10

(21) International Application Number:
PCT/US2004/031975

(22) International Filing Date:
25 September 2004 (25.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/897,897 23 July 2004 (23.07.2004) US

(71) Applicants *(for all designated States except US)*: **THE PROCTER & GAMBLE COMPANY** [US/US]; One Procter & Gamble Plaza, Cincinnati, OH 45202 (US). **AVENTIS PHARMACEUTICALS** [US/US]; 1041 Route 202-206, P.O. Box 6800, Bridgewater, NJ 08807-0800 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BURGIO, David, Ernest, Jr.** [US/US]; 6411 Cedar Hill Drive, Liberty Township, OH 45011 (US). **SCHOFIELD, Pamela, Jean** [US/US]; 1106 Paxton Avenue, Cincinnati, OH 45208 (US). **GATELY, Maurice, Kent** [US/US]; 16 Valley Forge Lane, Morris Plains, NJ 07950-3416 (US). **SHI, Jun** [US/US]; 47 Edgemere Road, Livingston, NJ 07039 (US).

(74) Common Representative: **THE PROCTER & GAMBLE COMPANY**; c/o T. David Reed, 6110 Center Hill Road, Cincinnati, OH 45224 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2006/022755 A1

(54) Title: RISEDRONATE COMPOSITIONS AND THEIR METHODS OF USE

(57) Abstract: A method comprising orally administering to a human or other mammal a pharmaceutical composition comprising from about 65% to about 110% of the cumulative effective dose of risedronate or a pharmaceutically acceptable acid, salt, ester, solvate, or polymorph thereof according to a continuous dosing schedule of one, two, or three consecutive days per month is useful for treating or preventing osteoporosis and other bone metabolic disorders.